top of page
veterinary research hemangiosarcoma


This section is intended to furnish veterinary professionals with a range of resources that focus on hemangiosarcoma. Our aim is to provide informative and beneficial materials that can support your work with both patients and clients. 

Clinical Trials

Clinical studies in the AVMA Animal Health Studies Database. Detailed information about participation in the studies is available at the database site.

AAHSD005063 - Clinical evaluation of propranolol in combination with doxorubicin for the treatment of hemangiosarcoma

AAHSD005542: Use of the PI3K inhibitor copanlisib to treat splenic hemangiosarcoma, University of Pennsylvania.

AAHSD005546: Ethos Precision Medicine Umbrella Study for Hemangiosarcoma, University of Missouri.

AAHSD005266 - Ethos Precision Medicine Umbrella Study for Hemangiosarcoma (Ethos-PUSH)

AAHSD005044 - Pharmacokinetics of a Novel Oil-Blend Rapamycin Formulation in Dogs with Cancer

Veterinary Sciences 

ISSN 2306-7381 

Jong-Hyuk Kim 1,2,3,*, Ashley J. Graef 1,3, Erin B. Dickerson 1,2,3 and Jaime F. Modiano 1,2,3,4,5 

 Received: 27 August 2015 / Accepted 20 October 2015 / Published: 6 November 2015 

Nicola Mason B.Vet.Med, PhD, DACVIM (Internal Medicine), FCPP, MRCVS, professor of medicine at the University of Pennsylvania School of Veterinary Medicine, examines the safety and efficacy of copanlisib—a phosphoinositide 3-kinase (PI3K) inhibitor—as a potential new treatment in the arsenal to slow the growth and spread of metastatic splenic hemangiosarcoma.

As a small animal clinician, you are no stranger to the stress and frustration that accompany diagnoses of Hemangiosarcoma. To better understand how to recognize, diagnose, treat, and monitor cases of Hemangiosarcoma, join Rachel Venable, DVM, MS, DACVIM (Oncology) for this FREE 1-hr webinar. She will review all things related to this dangerous neoplasm. Dr. Venable will share important tips and bits of information to remember including next generation disease screening options.

Understanding the genomic landscape of HSA may aid in developing therapeutic strategies for dogs and may also inform therapies for the rare and aggressive human cancer angiosarcoma.  The objectives of this study were to build a framework for leveraging real-world genomic and clinical data that could provide the foundation for precision medicine in veterinary oncology, and to determine the relationships between genomic and clinical features in canine splenic HSA.

bottom of page